Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Unutilized manufacturing capacity & CMO wind-down by Quarter
Unutilized manufacturing capacity & CMO wind-down charges ($M) ($M)
Moderna Unutilized manufacturing capacity & CMO wind-down: $23M in Q2 2026, down 55.8% from a year earlier.
Latest, Q2 2026
23
Period ended Jun 30, 2026
Change on a year earlier
-55.8%
52 in Q2 2025
History
11 quarters
Since Q4 2022
Sources
11
Documents cited below
Where the Q2 2026 figure comes from
“Cost of sales for the three months ended June 30, 2026 was $93 million, which included inventory write-downs of $41 million, unutilized manufacturing capacity costs of $23 million, and third-party royalties of $11 million.”
Source: Q2 2026 10-Q ↗
Reported in Form 10-Q / 10-K MD&A & Form 8-K Earnings Releases.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Unutilized manufacturing capacity & CMO wind-down charges ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 23 | -55.8% | Q2 2026 10-Q ↗ |
| Q2 2025 | Jun 30, 2025 | 52 | -5.5% | Q2 2025 Earnings Release (8-K) ↗ |
| Q1 2025 | Mar 31, 2025 | 21 | -22.2% | Q1 2025 10-Q ↗ |
| Q4 2024 | Dec 31, 2024 | 259 | +53.3% | Q4 2024 Earnings Release (8-K) ↗ |
| Q3 2024 | Sep 30, 2024 | 27 | – | Q3 2024 Earnings Release (8-K) ↗ |
| Q2 2024 | Jun 30, 2024 | 55 | -59.3% | Q2 2024 Earnings Release (8-K) ↗ |
| Q1 2024 | Mar 31, 2024 | 27 | -80.0% | Q1 2024 10-Q ↗ |
| Q4 2023 | Dec 31, 2023 | 169 | -55.1% | Q4 2023 Earnings Release (8-K) ↗ |
| Q2 2023 | Jun 30, 2023 | 135 | – | Q2 2023 10-Q ↗ |
| Q1 2023 | Mar 31, 2023 | 135 | – | Q1 2023 10-Q ↗ |
| Q4 2022 | Dec 31, 2022 | 376 | – | Q4 2022 Earnings Release (8-K) ↗ |
Cite this data
StockData. (2026). Moderna Unutilized manufacturing capacity & CMO wind-down ($M), quarterly Q4 2022–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/cos-unutilized-winddown
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.